Spotlight On... Seqirus to build new U.K. manufacturing outpost; GSK scouts for new CEO; GeoVax to collaborate with U.S. Army research institute; and more...

Seqirus--the world's second largest flu vaccine player formed from CSL's purchase of Novartis' ($NVS) flu vaccines--is expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there. The company is the second largest flu vaccine player, behind Sanofi ($SNY), with more than 2,000 employees worldwide. More from FiercePharmaManufacturing

> GlaxoSmithKline ($GSK) is starting a search for a new CEO. Story

> GeoVax announced plans to work with the United States Army Medical Research Institute of Infectious Diseases on a vaccine effort against hemorrhagic fever viruses. Release

> Researchers at Oxford University have begun a clinical trial of a prostate cancer vaccine candidate, aiming to vaccinate 48 men with low or intermediate prostate cancer risk to test safety and immune responses. Release

> A team led by University of Exeter in the U.K. has developed a vaccine with the potential to protect from melioidosis, or Whitmore's disease, an often fatal disease in tropical regions. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.